These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 19204418)

  • 81. New insights into the placebo and nocebo responses.
    Enck P; Benedetti F; Schedlowski M
    Neuron; 2008 Jul; 59(2):195-206. PubMed ID: 18667148
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Pharmacogenetics and the concept of individualized medicine.
    Shastry BS
    Pharmacogenomics J; 2006; 6(1):16-21. PubMed ID: 16302022
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Pharmacogenetics and pharmacogenomics of sexual dysfunction: current status, gaps and potential applications.
    Abdel-Hamid IA; Andersson KE
    Pharmacogenomics; 2009 Oct; 10(10):1625-44. PubMed ID: 19842936
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Enhance placebo, avoid nocebo: How contextual factors affect physiotherapy outcomes.
    Testa M; Rossettini G
    Man Ther; 2016 Aug; 24():65-74. PubMed ID: 27133031
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Patient Education in Psychopharmacology and the Risk of Nocebo-Related Treatment Inefficacy and Harm.
    Andrade C
    J Clin Psychiatry; 2017; 78(9):e1310-e1312. PubMed ID: 29345873
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Pharmacogenetic considerations in the elderly patient.
    Bright DR; Calinski DM; Kisor DF
    Consult Pharm; 2015 Apr; 30(4):228-39. PubMed ID: 25893701
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Clinical pharmacogenetics and potential application in personalized medicine.
    Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
    Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
    [TBL] [Abstract][Full Text] [Related]  

  • 88. European Headache Federation recommendations for placebo and nocebo terminology.
    Mitsikostas DD; Blease C; Carlino E; Colloca L; Geers AL; Howick J; Evers AWM; Flaten MA; Kelley JM; Kirsch I; Klinger R; MaassenVanDenBrink A; Moerman DE; Sfikakis PP; Vase L; Wager TD; Benedetti F;
    J Headache Pain; 2020 Sep; 21(1):117. PubMed ID: 32977761
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Prevention of adverse drug effects: a pharmacogenomic approach.
    Scott EN; Hasbullah JS; Carleton BC; Ross CJD
    Curr Opin Pediatr; 2020 Oct; 32(5):646-653. PubMed ID: 32796162
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Rethinking Clinical Trials and Personalized Medicine with Placebogenomics and Placebo Dose.
    Özdemir V; Endrenyi L
    OMICS; 2021 Jan; 25(1):1-12. PubMed ID: 33305994
    [TBL] [Abstract][Full Text] [Related]  

  • 91. "Harnessing the placebo effect: Exploring the influence of physician characteristics on placebo response": Correction.
    Howe LC; Goyer JP; Crum AJ
    Health Psychol; 2022 Nov; 41(11):873. PubMed ID: 35925707
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Promises and challenges of pharmacogenetics: an overview of study design, methodological and statistical issues.
    Ross S; Anand SS; Joseph P; Paré G
    JRSM Cardiovasc Dis; 2012 Apr; 1(1):. PubMed ID: 24175062
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Application of personalized medicine to chronic disease: a feasibility assessment.
    Dorfman R; Khayat Z; Sieminowski T; Golden B; Lyons R
    Clin Transl Med; 2013 Dec; 2(1):16. PubMed ID: 24351097
    [TBL] [Abstract][Full Text] [Related]  

  • 94. How informative is a negative finding in a small pharmacogenetic study?
    Bacanu SA; Whittaker JC; Nelson MR
    Pharmacogenomics J; 2012 Apr; 12(2):93-5. PubMed ID: 22158332
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Which four medication classes have important pharmacogenetic considerations?
    Smith SM
    JAAPA; 2023 Jan; 36(1):12-13. PubMed ID: 36573809
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Delivering pharmacogenetic testing to the masses: an achievable goal?
    Haga SB
    Pharmacogenomics; 2014 Jan; 15(1):1-4. PubMed ID: 24329184
    [No Abstract]   [Full Text] [Related]  

  • 97. Clinical use of pre-emptive pharmacogenetic programmes.
    Peñas-LLedó E; LLerena A
    Lancet; 2023 Feb; 401(10374):320-321. PubMed ID: 36739126
    [No Abstract]   [Full Text] [Related]  

  • 98. Overcoming Barriers: Strategies for Implementing Pharmacist-Led Pharmacogenetic Services in Swiss Clinical Practice.
    Wiss FM; Jakober D; Lampert ML; Allemann SS
    Genes (Basel); 2024 Jul; 15(7):. PubMed ID: 39062642
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Presenting a sham treatment as personalised increases the placebo effect in a randomised controlled trial.
    Sandra DA; Olson JA; Langer EJ; Roy M
    Elife; 2023 Jul; 12():. PubMed ID: 37405829
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Pharmacogenetic testing and counselling in the community pharmacy: mixed-methods study of a new pharmacist-led service.
    Jeiziner C; Meyer Zu Schwabedissen HE; Hersberger KE; Allemann SS
    Int J Clin Pharm; 2023 Dec; 45(6):1378-1386. PubMed ID: 37338707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.